Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high‐risk infants in Japan
Authors:
- 13 September 2010
- journal article
- research article
- Published by Wiley in Pediatrics International
- Vol. 53 (3) , 368-373
Abstract
Background: Respiratory syncytial virus (RSV) infection is a major cause of hospitalization during the winter among infants and young children. In 2002 palivizumab was introduced to high‐risk infants for RSV hospitalization in Japan. It is important to characterize the hospitalized children due to RSV infection after the introduction of palivizumab.Methods: A survey was conducted to collect the data from the hospitalized children at 12 participating hospitals during the winter of 2007.Results: From October 2007 through April 2008, 8163 children were admitted to participating hospitals, with RSV infection accounting for 811 of those hospitalizations. Mean age in children with RSV infection at hospitalization was 12.4 ± 12.7 months, and children under 24 months of age accounted for 86.4%. The mean gestational age of those at birth was 38.0 ± 2.6 weeks, with 82.4% of the children born at term. Palivizumab was administered in 24 cases of RSV infection, while there were 28 patients who were not treated with palivizumab, even though they met the indication for palivizumab. Death, in a total of five cases, occurred in children who were not treated with palivizumab.Conclusions: Palivizumab has been widely used in high‐risk infants who were covered by health insurance, and most of the hospitalized children with RSV infection in the study hospitals were not treated with palivizumab.Keywords
This publication has 13 references indexed in Scilit:
- Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational ageEuropean Journal of Clinical Microbiology & Infectious Diseases, 2008
- Results of clinical surveillance during the Japanese first palivizumab season in 2002–2003Pediatrics International, 2006
- Guidelines for the use of palivizumab in infants and young children with congenital heart diseasePediatrics International, 2006
- Prevention of respiratory syncytial virus infections in high‐risk infantsby monoclonal antibody (palivizumab)Pediatrics International, 2002
- Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIVPediatrics, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Respiratory Syncytial Virus1997
- Respiratory syncytial virus infection in lower respiratory tract and asthma attack in hospitalized children in North Hokkaido, JapanPediatrics International, 1993
- Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian childrenThe Journal of Pediatrics, 1992
- Visiting Experts Find the "Mystery Disease" of Naples Is a Common VirusScience, 1979